Attune Neurosciences

What Attune Neurosciences does

Attune Neurosciences is a private, pre-commercial medical device company founded in 2019 and headquartered in San Francisco, California, developing what it describes as the world's first wearable platform for transcranial ultrasound stimulation (TUS) targeting deep brain structures with millimeter-level accuracy. The company's core product is a non-invasive focused ultrasound neuromodulation device intended for treating brain disorders including depression, anxiety, chronic pain, PTSD, schizophrenia, and opioid use disorder, as well as applications in cognitive performance enhancement. The platform leverages established ultrasound technology adapted into a wearable form factor, positioning it as an alternative to pharmacological treatments (which lack precision and carry side effects) and to surgical electrical stimulation approaches like deep brain stimulation. The device is currently investigational and limited by U.S. law to investigational use.

The company operates a clinical-research-driven go-to-market, conducting participant studies across neurological and psychiatric populations rather than commercial sales. Distribution occurs through clinical research programs with recruitment via phone screening, community outreach, and veteran advocacy partnerships. The company has established collaborations with federal research agencies (DARPA, NIH, ARPA-H via the EVIDENT initiative), academic institutions (UCSF, Vanderbilt, Brown University, University of Calgary), defense organizations (USSOCOM), aerospace (Airbus), and brain health nonprofits (One Mind, AIT Children's Project). Investors include Genoa Ventures, Satori Capital, Prime Movers Lab, and Social Starts, with a disclosed $3.75 million seed round in April 2021.

Attune has generated peer-reviewed research in Neuron, Brain Stimulation Journal, PNAS, and PLOS Biology, including first-in-human studies targeting striatal circuits in schizophrenia and thalamic stimulation in treatment-resistant depression. The company co-hosts the FUS Forward podcast as a thought leadership channel and is actively hiring across engineering, software, and clinical operations roles. Revenue generation has not begun, with the company pursuing a regulatory pathway toward eventual commercialization through FDA clinical trials.

Name

Attune Neurosciences

Legal name

Attune Neurosciences, Inc.

Website

https://attuneneuro.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Attune Neurosciences is a pre-commercial medical device company developing the first wearable transcranial focused ultrasound neuromodulation platform for non-invasive deep brain stimulation, targeting patients with depression, chronic pain, PTSD, schizophrenia, and other neurological conditions through clinical research partnerships.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)

akta.pro secondary industries

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

Keywords

• Transcranial ultrasound stimulation
• Wearable neuromodulation devices
• Non-invasive brain stimulation
• Focused ultrasound therapy
• Deep brain neuromodulation

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-commercial / Research Stage: Attune Neurosciences is a pre-commercial company developing an investigational medical device. The company is conducting clinical research studies and has not yet commercialized its product. Revenue generation has not begun.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Attune Neurosciences develops an investigational, wearable transcranial focused ultrasound stimulation (TUS) medical device that delivers targeted, adaptive ultrasound therapy to deep brain structures with millimeter-level accuracy. The device is intended as a non-invasive alternative to medications and surgically implanted electrical stimulation for neurological and psychiatric conditions including depression, anxiety, chronic pain, PTSD, schizophrenia, and opioid use disorder. The platform is currently limited by U.S. law to investigational use and is distributed only through clinical research studies, not commercial channels.

Product overview

Attune Neurosciences offers a single unified product: the Attune Wearable Ultrasound Neuromodulation Platform. This is a wearable medical device that delivers targeted, adaptive ultrasound therapy to the deep brain for treatment of brain disorders (including depression, chronic pain, PTSD, and schizophrenia) and improved cognitive performance. The platform represents the world's first wearable focused ultrasound neuromodulation system designed for everyday use, making this breakthrough technology practical, personalized, and accessible.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Participants in chronic pain study reported feeling better within first or second week of treatment with continued improvement over time
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• ARPA-H EVIDENT InitiativecoreStrategic or Co-development Partner · 21 April 2026ARPA-H, an agency within the U.S. Department of Health and Human Services, announced research teams for its EVIDENT initiative funding up to $139.4 million for behavioral health treatments. Attune is contributing to developing FDA-ready clinical endpoints for rapid-acting therapies including neuromodulation. At least $50 million allocated to match state government investments in psychedelic research.
• DARPAcoreStrategic or Co-development PartnerU.S. Defense Advanced Research Projects Agency driving breakthrough innovations in science and national security. Listed as collaborator on Attune's website.
• NIHcoreStrategic or Co-development PartnerNational Institutes of Health, the nation's leading center for biomedical and public health research. Listed as collaborator providing research funding and validation.
• UCSFcoreStrategic or Co-development PartnerUniversity of California, San Francisco - world-renowned for pioneering medical research and clinical excellence. Listed as collaborator with likely research partnerships.
• USSOCOMcoreStrategic or Co-development PartnerUnited States Special Operations Command, overseeing and integrating all U.S. special operations forces. Interest in neuromodulation for cognitive performance and treatment of military-related conditions.
• One MindsupportingStrategic or Co-development PartnerGlobal nonprofit accelerating brain health research, innovation, and advocacy. Listed as collaborator with interest in advancing brain health treatments.
• AirbussupportingStrategic or Co-development PartnerGlobal aerospace leader advancing next-generation aviation and defense technologies. Listed as collaborator - may have interest in cognitive performance applications for aerospace personnel.
• AIT Children's ProjectsupportingStrategic or Co-development PartnerNonprofit improving health outcomes for children through research and compassionate care. Listed as collaborator with interest in pediatric neurological applications.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• InSightec: InSightec develops MR-guided focused ultrasound systems for non-invasive brain procedures (e.g., essential tremor, Parkinson's tremor). It is the most directly comparable company in transcranial focused ultrasound therapeutics, although its current platform is a clinical installation rather than a wearable consumer device.
• Soterix Medical: Soterix Medical develops non-invasive brain stimulation platforms using transcranial direct current stimulation (tDCS) and related electrical techniques for research and clinical use. It is a direct peer in the non-invasive neuromodulation device category, although it uses electrical rather than ultrasonic energy.
• NeuroPace: NeuroPace markets the RNS System, an implanted responsive neurostimulation device for refractory epilepsy. It is a peer in the brain stimulation medical device space focused on neurological disorders, though its modality (invasive implanted device) contrasts with Attune's non-invasive wearable approach.

Broad incumbents

• BrainsWay: BrainsWay markets deep transcranial magnetic stimulation (dTMS) systems cleared by the FDA for depression, OCD, and smoking cessation. It is a relevant incumbent non-invasive neuromodulation competitor pursuing overlapping psychiatric indications to Attune.
• Neuronetics: Neuronetics commercializes NeuroStar, an FDA-cleared TMS system for major depressive disorder. It is an established commercial player in non-invasive brain stimulation treating the same depression population Attune is targeting with TUS.
• electroCore: electroCore markets non-invasive vagus nerve stimulation (nVNS) devices for headache, epilepsy, and depression indications. It is a commercialized non-invasive neuromodulation peer targeting overlapping neurological and psychiatric use cases.
• Magstim: Magstim manufactures transcranial magnetic stimulation systems widely used in neuroscience research and clinical TMS practice. It is an established incumbent in the non-invasive brain stimulation category with overlap to Attune's research and clinical positioning.

Emerging players

• Cordance Medical: Cordance Medical is developing non-invasive focused ultrasound to open the blood-brain barrier for drug delivery and to modulate brain activity. It is an emerging peer working in transcranial focused ultrasound with overlapping technology and clinical focus areas to Attune.
• SonALM.indie (Sonacare Medical): SonALM.indie (now Sonala Sciences) is developing low-intensity focused ultrasound for non-thermal, non-ablative neuromodulation. It is an emerging peer with the most closely aligned technology modality to Attune's transcranial ultrasound stimulation approach.

Others

• Synchron: Synchron is developing a minimally invasive brain-computer interface (BCI) for patients with paralysis. It is an adjacent neurotechnology peer rather than a direct competitor, but both companies are part of the broader non-pharmacological brain interface investment narrative.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Attune Neurosciences